Avidity Biosciences, Inc.

NasdaqGM RNA

Avidity Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 1.59 B

Avidity Biosciences, Inc. Cash and Short-Term Investments is USD 1.59 B for the quarter ending September 30, 2024, a 192.78% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Avidity Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 542.58 M, a 33.79% change year over year.
Avidity Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 405.55 M, a -1.81% change year over year.
Avidity Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 413.03 M, a 21.07% change year over year.
Avidity Biosciences, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 341.14 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGM: RNA

Avidity Biosciences, Inc.

CEO	Ms. Sarah Boyce
IPO Date	June 12, 2020
Location	United States
Headquarters	10578 Science Center Drive
Employees	253
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Key trends

Past 5 years